Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs.

Cancer biology & therapy - 1 Apr 2006

Wang Haijuan, Qian Haili, Yu Jian, Zhang Xueyan, Zhang Lin, Fu Ming, Liang Xiao, Zhan Qimin, Lin Chen

Abstract excerpt

Esophageal cancer is one of the most lethal human tumors, characterized by relative chemoresistance and poor prognosis. Researchers have been seeking for multimodality to improve its outcome of therapy. PUMA (p53 upregulated modulator of apoptosis) is a potent proapoptotic molecule that is rapidly induced in cells following DNA damage and is required for p53-induced apoptosis. We evaluated the therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Separation
Share to Cell Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Flow Cytometry

Share to Genes, p53

Share to Immunodeficiency Virus, Feline

Share to Inhibitory Concentration 50

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 16481741
DOI: 10.4161/cbt.5.4.2477

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs.PMID 16481741Read ↗

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsSemantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

The role of survivin as a new target of diagnosis and treatment in human cancer.Semantic proximity Read ↗

The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells.Semantic proximity Read ↗

Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus.Semantic proximity Read ↗

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Semantic proximity Read ↗

Traditional Chinese medicine targeting apoptotic mechanisms for esophageal cancer therapySemantic proximity Read ↗

[Expression of survivin and its significance in esophageal cancer].Semantic proximity Read ↗

DpdtbA-Induced Growth Inhibition in Human Esophageal Cancer Cells Involved Inactivation of the p53/EGFR/AKT PathwaySemantic proximity Read ↗

The p53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-xL and Mcl-1Semantic proximity Read ↗

Oncolytic virotherapy as a novel strategy for pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.